Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. If you are trying to figure out whether Exact Sciences is ...

Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 ...

) has been revised to $8.01 / share. This is an increase of 22.34% from the prior estimate of $6.55 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...

GSP Crop Science IPO price band is set at ₹304 to ₹320 per share, with subscription from March 16 to March 18. Allocation for anchor investors is on March 13, and shares will list on BSE and NSE on ...

CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...

BofA lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $88 and keeps a Buy rating on the shares after the company announced Q3 results that fell short of expectations and lowered ...